Kidney Fibrosis - Pipeline Review, H1 2017

Published: May, 2017 | Pages: 131 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Kidney Fibrosis - Pipeline Review, H1 2017, provides an overview of the Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline landscape.

Accumulation of extracellular matrix in the kidney causes kidney fibrosis. It is a progressive disorder characterized by glomerulosclerosis and tubulointerstitial fibrosis and may lead to detrimental effects on the kidney functioning. Predisposing factors are trauma, injury, infections, surgery, environmental factors and exposure to chemicals or radiation. Symptoms include pain, problems related to urination, nausea and vomiting. The condition may be managed with medication and kidney transplant.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Kidney Fibrosis - Pipeline Review, H1 2017, provides comprehensive information on the therapeutics under development for Kidney Fibrosis (Genito Urinary System And Sex Hormones), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline guide also reviews of key players involved in therapeutic development for Kidney Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase I, Preclinical and Discovery stages are 4, 25 and 5 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 5 molecules, respectively.

Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Kidney Fibrosis (Genito Urinary System And Sex Hormones).
- The pipeline guide reviews pipeline therapeutics for Kidney Fibrosis (Genito Urinary System And Sex Hormones) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Kidney Fibrosis (Genito Urinary System And Sex Hormones) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Kidney Fibrosis (Genito Urinary System And Sex Hormones) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Kidney Fibrosis (Genito Urinary System And Sex Hormones)

Reasons To Buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Kidney Fibrosis (Genito Urinary System And Sex Hormones).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Kidney Fibrosis (Genito Urinary System And Sex Hormones) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

 Table of Contents

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Kidney Fibrosis - Overview
Kidney Fibrosis - Therapeutics Development
Pipeline Overview
Pipeline by Companies
Pipeline by Universities/Institutes
Products under Development by Companies
Products under Development by Universities/Institutes
Kidney Fibrosis - Therapeutics Assessment
Assessment by Target
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Kidney Fibrosis - Companies Involved in Therapeutics Development
AbbVie Inc
Allergan Plc
Angion Biomedica Corp
Apollo Endosurgery Inc
BiOrion Technologies BV
Cellmid Ltd
Epigen Biosciences Inc
Evotec AG
Galectin Therapeutics Inc
GenKyoTex SA
Horizon Pharma Plc
Intercept Pharmaceuticals Inc
Isarna Therapeutics GmbH
MorphoSys AG
Pharmaxis Ltd
ProMetic Life Sciences Inc
Regulus Therapeutics Inc
Sirnaomics Inc
Symic Biomedical Inc
Vascular Biogenics Ltd
Kidney Fibrosis - Drug Profiles
ANG-3070 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ANG-3586 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ANG-4021 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
BOT-191 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CAB-102 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cenicriviroc mesylate - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
CT-140 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
cysteamine DR - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Inhibit Galectin-3 for Liver Fibrosis, Pulmonary Fibrosis and Kidney Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drugs for Tissue Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Gene Therapy to Activate Smad7 for Hypertensive Cardiomyopathy and Kidney Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GKT-136901 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
GRMD-02 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ICG-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
INT-767 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
IP-9 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ISTH-0047 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
LJ-1888 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Lpathomab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
melittin - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MOR-107 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
P-007 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PBI-4050 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PXS-4820 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PXS-5033A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Recombinant Protein to Agonize ALK and BMP Receptors for Alport Syndrome, Kidney Diseases, Metabolic Disorders and Osteoarthritis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RG-012 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SB-300 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize AlphaV and Beta6 for Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Antagonize LPA1 Receptor for Metastatic Breast Cancer and Renal Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit Cyclophilin D for Obesity and Renal Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecules to Inhibit LOXL2 for Idiopathic Pulmonary Fibrosis, Kidney Fibrosis, Liver Fibrosis and Non-Alcoholic Steatohepatitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SOL-1 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
STP-705 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Agonize BMP7 Receptor for Renal Fibrosis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
TEW-7197 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VB-201 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VB-703 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Wnt-001 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Kidney Fibrosis - Dormant Projects
Kidney Fibrosis - Product Development Milestones
Featured News & Press Releases
Apr 25, 2017: Galectin Therapeutics Receives Notice of Japanese Decision to Grant a Composition of Matter Patent for GR-MD-02
Feb 21, 2017: MorphoSys's Subsidiary Lanthio Pharma Initiates First-in-Human Clinical Study with Lanthipeptide MOR107
Nov 18, 2016: ProMetic presents PBI-4050's positive effect on diabetic patients' kidneys at the American Society of Nephrology Annual Meeting
Jul 12, 2016: Galectin Therapeutics Receives Notice of Australian Patent to be Granted for the Use of GR-MD-02 in Liver, Kidney, Lung or Heart Fibrosis
Nov 12, 2015: Regulus Announces Grant of Patent Covering Lead microRNA Therapeutics
Nov 09, 2015: ProMetic's PBI-4050 data on renal fibrosis and pancreatic function featured at the American Society of Nephrology's annual meeting
Oct 29, 2015: ProMetic's PBI-4050 Cleared to Commence Clinical Trial in Patients With Type 2 Diabetes and Multi-Organ Fibrosis in Europe
Oct 05, 2015: Regulus to Present Additional Preclinical Data Supporting RG-012 as a Novel microRNA Therapeutic in Development for Alport Syndrome at ASN's Kidney Week 2015
Aug 13, 2015: Galectin Therapeutics Receives U.S. Patent Notice of Allowance for Use of Pectin Compounds to Reduce Fibrosis in Multiple Diseases
Oct 14, 2014: Regulus Therapeutics To Present New Preclinical Data on Multiple Programs At 10th Annual Oligonucleotide Therapeutics Society Meeting
Aug 05, 2014: Galectin Therapeutics Receives U.S. Patent for GR-MD-02 Composition of Matter
Jul 25, 2014: Galectin Therapeutics to Host Webcast to Discuss Findings From Cohort 2 of Phase 1 Clinical Trial of GR-MD-02 in Fatty Liver Disease With Advanced Fibrosis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables

Number of Products under Development for Kidney Fibrosis, H1 2017
Number of Products under Development by Companies, H1 2017
Number of Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Number of Products under Development by Universities/Institutes, H1 2017
Products under Development by Companies, H1 2017
Products under Development by Companies, H1 2017 (Contd..1), H1 2017
Products under Development by Universities/Institutes, H1 2017
Number of Products by Stage and Target, H1 2017
Number of Products by Stage and Target, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017
Number of Products by Stage and Mechanism of Action, H1 2017 (Contd..1), H1 2017
Number of Products by Stage and Route of Administration, H1 2017
Number of Products by Stage and Molecule Type, H1 2017
Kidney Fibrosis - Pipeline by AbbVie Inc, H1 2017
Kidney Fibrosis - Pipeline by Allergan Plc, H1 2017
Kidney Fibrosis - Pipeline by Angion Biomedica Corp, H1 2017
Kidney Fibrosis - Pipeline by Apollo Endosurgery Inc, H1 2017
Kidney Fibrosis - Pipeline by BiOrion Technologies BV, H1 2017
Kidney Fibrosis - Pipeline by Cellmid Ltd, H1 2017
Kidney Fibrosis - Pipeline by Epigen Biosciences Inc, H1 2017
Kidney Fibrosis - Pipeline by Evotec AG, H1 2017
Kidney Fibrosis - Pipeline by Galectin Therapeutics Inc, H1 2017
Kidney Fibrosis - Pipeline by GenKyoTex SA, H1 2017
Kidney Fibrosis - Pipeline by Horizon Pharma Plc, H1 2017
Kidney Fibrosis - Pipeline by Intercept Pharmaceuticals Inc, H1 2017
Kidney Fibrosis - Pipeline by Isarna Therapeutics GmbH, H1 2017
Kidney Fibrosis - Pipeline by MorphoSys AG, H1 2017
Kidney Fibrosis - Pipeline by Pharmaxis Ltd, H1 2017
Kidney Fibrosis - Pipeline by ProMetic Life Sciences Inc, H1 2017
Kidney Fibrosis - Pipeline by Regulus Therapeutics Inc, H1 2017
Kidney Fibrosis - Pipeline by Sirnaomics Inc, H1 2017
Kidney Fibrosis - Pipeline by Symic Biomedical Inc, H1 2017
Kidney Fibrosis - Pipeline by Vascular Biogenics Ltd, H1 2017
Kidney Fibrosis - Dormant Projects, H1 2017